Aurinia Pharmaceuticals Inc. AUPH revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Aurinia Pharmaceuticals Inc. reported revenue across 2 products and services; the largest, Product, was $271M, 95.9% of the filed sum (+25.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$271M95.9%+25.5% yoy
- License Collaboration And Royalty Revenue$11.7M4.1%-38.2% yoy
Members sum to the consolidated $283M for this period.
- United States$264M93.2%+25.6% yoy
- Japan$19.2M6.8%-23.3% yoy
Members sum to the consolidated $283M for this period.
- Product$73.6M94.7%+22.7% yoy
- License Collaboration And Royalty Revenue$4.14M5.3%+66.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.